Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model

Inheritance of a gene mutation leads to the initiation of 5 to 10% of most cancers, including colon cancer cases. We developed a chemoprevention strategy using a novel combination of the non-steroidal anti-inflammatory (NSAID) sulindac plus the anthelminthic benzimidazole, mebendazole. This oral dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Williamson, Tara, Bai, Ren-Yuan, Staedtke, Verena, Huso, David, Riggins, Gregory J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356574/
https://www.ncbi.nlm.nih.gov/pubmed/27612418
http://dx.doi.org/10.18632/oncotarget.11851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356574/
https://www.ncbi.nlm.nih.gov/pubmed/27612418
http://dx.doi.org/10.18632/oncotarget.11851

Ejemplares similares